Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'VX-478' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 13 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Sadler, BM; Gillotin, C; Lou, Y; Stein, DS
      In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    2. Sadler, BM; Gillotin, C; Lou, Y; Stein, DS
      Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    3. Fung, HB; Kirschenbaum, HL; Hameed, R
      Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor

      CLINICAL THERAPEUTICS
    4. Ziermann, R; Limoli, K; Das, K; Arnold, E; Petropoulos, CJ; Parkin, NT
      A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir

      JOURNAL OF VIROLOGY
    5. Markland, W; Rao, BG; Parsons, JD; Black, J; Zuchowski, L; Tisdale, M; Tung, R
      Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir

      JOURNAL OF VIROLOGY
    6. Reddy, P; Ross, J
      Amprenavir - A protease inhibitor for the treatment of patients with HIV-1infection

      FORMULARY
    7. Polk, RE; Crouch, MA; Israel, DS; Pastor, A; Sadler, BM; Chittick, GE; Symonds, WT; Gouldin, W; Lou, Y
      Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men

      PHARMACOTHERAPY
    8. Haubrich, R; Thompson, M; Schooley, R; Lang, W; Stein, A; Sereni, D; van der Ende, ME; Antunes, F; Richman, D; Pagano, G; Kahl, L; Fetter, A; Brown, DJ; Clumeck, N
      A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviralexperience

      AIDS
    9. Sadler, BM; Hanson, CD; Chittick, GE; Symonds, WT; Roskell, NS
      Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    10. Murphy, RL; Gulick, RM; DeGruttola, V; D'Aquila, RT; Eron, JJ; Sommadossi, JP; Currier, JS; Smeaton, L; Frank, I; Caliendo, AM; Gerber, JG; Tung, R; Kuritzkes, DR
      Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection

      JOURNAL OF INFECTIOUS DISEASES
    11. ADKINS JC; FAULDS D
      AMPRENAVIR

      Drugs
    12. CHRUSCIEL RA; ROMINES KR
      RECENT DEVELOPMENTS IN HIV PROTEASE INHIBITOR RESEARCH

      Expert opinion on therapeutic patents
    13. STCLAIR MH; MILLARD J; ROONEY J; TISDALE M; PARRY N; SADLER BM; BLUM MR; PAINTER G
      IN-VITRO ANTIVIRAL ACTIVITY OF 141W94 (VX-478) IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

      Antiviral research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/10/20 alle ore 07:10:23